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Abstract 11 
Clostridium difficile flagellin FliC is a highly immunogenic pathogen-associated molecular pattern 12 
playing a key role in C. difficile pathogenesis and gut colonization. Here, we designed an oral vaccine 13 
against C. difficile with FliC encapsulated into pectin beads for colonic release. Bead stability and 14 
FliC retention was confirmed in vitro using simulated intestinal media (SIM), while bead degradation 15 
and FliC release was observed upon incubation in simulated colonic media (SCM). The importance 16 
of FliC encapsulation into pectin beads for protection against C. difficile was assessed in a 17 
vaccination assay using a lethal hamster model of C. difficile infection. Three groups of hamsters 18 
orally received either FliC-loaded beads or unloaded beads in gastro-resistant capsule to limit gastric 19 
degradation or free FliC. Two other groups were immunized with free FliC, one intra-rectally and the 20 
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other intra-peritoneally. Hamsters were then challenged with a lethal dose of C. difficile VPI 10463. 21 
Fifty percent of hamsters orally immunized with FliC-loaded beads survived whereas all hamsters 22 
orally immunized with free FliC died within 7 days post challenge. No significant protection was 23 
observed in the other groups. Only intra-peritoneally immunized hamsters presented anti-FliC IgG 24 
antibodies in sera after immunizations. These results suggest that an oral immunization with FliC-25 
loaded beads probably induced a mucosal immune response, therefore providing a protective effect. 26 
This study confirms the importance of FliC encapsulation into pectin beads for a protective oral 27 
vaccine against C. difficile. 28 
Keywords: Clostridium difficile; oral vaccination; flagellin; pectin beads; colonic delivery 29 
 30 
1 Introduction 31 
Clostridium difficile (Clostridioides) difficile [1] is a Gram-positive, anaerobic spore-forming 32 
bacterium and is the leading cause of antibiotic-associated diarrhea. Gut microbiota dysbiosis enables 33 
C. difficile colonization of the intestinal tract. After contamination, C. difficile spores germinate, 34 
vegetative forms multiply, and toxins are released, disrupting epithelium integrity and inducing an 35 
inflammatory response in the colon [2]. C. difficile is a non-invasive pathogen, thus, promoting local 36 
intestinal immunity could trigger early protection against C. difficile infection (CDI) [3]. Even 37 
though the intra-rectal route has shown promising results previously by inducing a protective 38 
immune response directed to C. difficile [4-6], developing the oral route of immunization 39 
represents a rational choice to induce a gut mucosal immune response with a better patient 40 
acceptance and comfort. To overcome the gastrointestinal barrier, antigen encapsulation is 41 
recommended to maintain its integrity and its immunogenicity. Biocompatible and biodegradable 42 
polymers are interesting materials for encapsulation. For instance, pectin, a non-toxic polysaccharide, 43 
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has previously shown promising capacity for protein encapsulation and colonic delivery [7, 8]. 44 
Indeed, pectin is not degraded by gastric or intestinal enzymes but is almost totally degraded by 45 
pectinolytic enzymes produced by the microbiota present in the colon [7, 9].  46 
Current strategies for vaccine development against C. difficile target either toxins or colonization 47 
factors. Systemic vaccines targeting toxins are currently being tested in clinical trials 48 
(NCT01887912; NCT03090191; NCT02316470) and have shown efficacy in protecting against CDI 49 
in animal models [10, 11]. However, targeting colonization factors could prevent C. difficile 50 
colonization, growth and symptomatic infection therefore limiting dissemination of the bacteria in 51 
the environment. Several vaccine candidates targeting colonization factors showed promising results 52 
[4, 8, 12]. For instance, flagellin which is highly immunogenic, harbors a unique pathogen-associated 53 
molecular pattern implicated in toll-like receptor-5 (TLR-5) recognition. However, the central 54 
domain of the flagellin is highly variable among different species [13, 14]. Regarding C. difficile 55 
flagellin, FliC is a 39 kDa structural protein of the flagellum. The central domain, the N- and C-56 
terminal domains of FliC are well conserved among the different strains of C. difficile. FliC 57 
antibodies have been detected in patient sera [15] and non-CDI patients presented significantly more 58 
anti-FliC serum antibodies than CDI patients [16]. Interestingly, the immunological properties of 59 
FliC enable it to act as adjuvant [17] and as antigen, so, FliC represents a promising vaccine 60 
candidate [12, 18]. Ghose et al. intraperitoneally immunized hamsters and mice with FliC and 61 
described the induction of a systemic IgG response protective against CDI [12]. 62 
Developing a mucosal vaccine targeting C. difficile gut colonization could enable early 63 
protection against CDI. Oral vaccines can be expected to have much greater acceptability than 64 
injectable vaccines. Oral vaccine administration could also lead to simplified manufacturing 65 
vaccine, thereby increasing the potential for local vaccine production. Here we describe the 66 
development and the efficacy of a mucosal vaccine strategy with FliC against C. difficile virulence in 67 
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hamster. To this end, here we first assess the suitability of pectin beads to deliver FliC into the colon 68 
and we evaluate FliC-loaded pectin beads in gastro-resistant capsules as an oral vaccine candidate 69 
against C. difficile in a lethal hamster model of CDI.  70 
2 Material and methods 71 
2.1 Preparation of pectin beads 72 
Recombinant FliC was obtained and purified as previously described [13] with exception that the 73 
purified protein was dialyzed against TRIS buffer (25 mM, pH 7.5). Pectin beads were prepared as 74 
previously detailed [8], pectin solution was obtained with Unipectine
TM
 OG175C (Cargill) dissolved 75 
in TRIS buffer (25 mM, pH 7.5) at the concentration of 6% (w/V). Unloaded beads were prepared 76 
with the pectin solution only and FliC-loaded beads with pectin solution and recombinant FliC. The 77 
pectin solution containing FliC or not was then dropped into a cross-linking solution of Zn acetate 78 
(12%, w/V). Beads, formed instantaneously by contact with zinc ions, were left in the cross-linking 79 
solution for 30 minutes at room temperature under magnetic stirring. Beads were washed three times 80 
with distilled water and then dried 3 hours at 37°C. To determine encapsulation efficiency (EE), 81 
FliC-loaded beads were disintegrated in TRIS buffer (25 mM, pH 7.5) added with EDTA (50 mM). 82 
Then, proteins were dosed using Bradford dye-binding method. EE(%) was determined by the 83 
following formula : (actual amount of FliC encapsulated / theoretical amount of FliC 84 
encapsulated) *100. 85 
2.2 Analysis of protein release from beads in simulated digestive media 86 
Analysis of FliC release was carried out in two different simulated digestive media as previously 87 
described [8]: 5 h in Simulated Intestinal Medium (SIM, HEPES/NaCl buffer, pH 6.8) containing 88 
pancreatin (1% w/V) followed by 5 h in Simulated Colonic Medium (SCM, HEPES/NaCl buffer, pH 89 
6) containing ≥760 U/mL of pectinase from Aspergillus aculeatus (Sigma). Presence of FliC and 90 
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pectinase in the same medium makes difficult to dose proteins by Bradford dye-binding method. 91 
Therefore, loaded beads were prepared using rhodamine-labelled FliC. Labeling and release protocol 92 
were performed as previously described [8] and the amount of FliC released was determined by 93 
spectrofluorometry in duplicate. 94 
2.3 Gastro-resistant coating of capsules containing beads for oral immunization 95 
To protect beads from the harsh gastric acid environment, loaded and unloaded beads were placed 96 
into gelatin capsules (size 9, Harvard Apparatus) coated with a hydroxypropyl methylcellulose 97 
phthalate (HPMCP 50) film. Coating was performed by dipping capsules into a 10% (w/V) solution 98 
of HPMCP 50 in acetone/ethanol (1:1 v:v) and drying them at room temperature [8]. This process 99 
was repeated six times. The efficacy of the gastro-resistant coating was checked by a disintegration 100 
test according to European pharmacopoeia (capsules undamaged after 2 h in HCl 0.1 M) [8]. 101 
2.4 Animals 102 
The vaccination study was carried out in a model of infection using Mesocricetus auratus female 103 
hamsters (weight, 80–100 g, Janvier Laboratories). Protocols involving animals and their care were 104 
conducted in conformity with the institutional guidelines that are in compliance with national and 105 
international laws and policies. The protocol was approved by the Committee on the Ethics of 106 
Animal Experiments University of Paris-Sud and the French Minister of Research (APAFIS#4577-107 
2016020913152994 v4). All efforts were made to minimize animal suffering. 108 
2.5 Vaccination protocol 109 
Five groups of 6 animals were used. Each vaccinated animals received a total of 300 µg of FliC in 110 
three administrations of 100 µg of FliC every fifteen days (at day 0, day 15 and day 30). One group 111 
was immunized with FliC-loaded pectin beads given orally and a group orally received unloaded 112 
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beads. Three other groups were immunized with recombinant free FliC by oral, intra-rectal or intra-113 
peritoneal route. Fifteen days after the last immunization (at day 45) and before C. difficile 114 
challenge, hamsters were orally given clindamycin at a single dose of 50 mg/kg and gentamicin twice 115 
a day during 5 days (from day 45 to day 49) at a dose of 2.5 mg/kg to disrupt the intestinal 116 
microbiota. Then at day 50, hamsters were orally challenged with 7,5x10
4
 spores of C. difficile strain 117 
VPI 10463 (Fig. 1). Two days after challenge, C. difficile colonization was checked by detection of 118 
C. difficile vegetative cells in the feces by plating adequate dilutions on Columbia agar 119 
containing 5% of horse blood, 25% (w/v) of D-cycloserine, and 0.8% (w/v) of cefoxitin and 120 
taurocholate. 121 
2.6 Evaluation of specific antibody level in sera after immunization 122 
To evaluate the antibody response in sera, blood samples were withdrawn before the first 123 
immunization and 15 days after the last immunization, before C. difficile challenge. Indirect ELISA 124 
was used to detect antibodies in the sera as previously described [6]. Briefly, wells of 96-well 125 
microtitre plates (MaxiSorp, Nunc) were coated with 100 µL of a 5 µg/mL solution of recombinant 126 
purified FliC. Sera were tested in duplicate at dilution 1:500 in 100 µL final volume. After five 127 
washings with phosphate buffer (PBS) and Tween-20 (0.1%), an aliquot of 100 µL per well of a 128 
rabbit anti-hamster IgG conjugated with biotin (1:8,000 dilution; Biovalley) was added and plates 129 
were incubated for 30 min at 37°C. Then, after five washings, 100 µL per well of streptavidin–HRP 130 
(1:10,000 dilution; ThermoScientific) were added and plates were incubated for 30 min at 37°C. 131 
Assays with antigen in the absence of sera served as negative controls. Immunoglobulin levels are 132 
expressed as OD units at 450 nm. 133 
2.7 Statistical analysis 134 
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Animal surviving rate was analyzed using Kaplan–Meier estimates. Survival rates between groups 135 
were compared using log rank test, p-values < 0.05 were considered as statistically significant. 136 
Mann-Withney U-test was performed to analyzed specific anti-FliC antibody levels in sera after 137 
immunizations, p-values < 0.05 were considered as statistically significant. 138 
3 Results 139 
3.1 Flagellin encapsulation in pectin beads and in vitro release 140 
In order to perform oral vaccination, we encapsulated the recombinant C. difficile flagellin FliC into 141 
pectin beads. About 40 to 45 beads were obtained per milliliter of pectin solution. After drying, beads 142 
had an ellipsoid shape with a 1.2-1.5 mm diameter and weighed between 1.5 and 2 mg (Fig. 2). The 143 
total amount of encapsulated FliC was dosed after total disintegration of beads. FliC-loaded bead 144 
contained a total amount of 3 ± 1 µg of FliC by bead, this corresponds to an encapsulation efficiency 145 
of about 30 ± 10% (n=5). In vitro characterization confirms beads stability in SIM and protein release 146 
in SCM containing pectinase. Less than 10% of FliC was released after 5 h of incubation in SIM and 147 
dried beads swelled keeping their shape. After being placed in SCM, beads started to disintegrate 148 
leading to the release of FliC. Between 2 and 3 h were sufficient to release more than 80% of 149 
entrapped FliC (Fig. 3). This in vitro characterization of FliC-loaded beads confirms the interest of 150 
using this encapsulation strategy for colonic delivery of an antigen after oral administration. 151 
3.2 Vaccination with flagellin against CDI in the hamster model 152 
C. difficile flagellin FliC is a promising vaccine candidate. To evaluate the efficacy of mucosal 153 
vaccination with FliC against C. difficile virulence, we immunized hamsters with the same amount of 154 
FliC via different mucosal routes and compare them with the intra-peritoneal parenteral route. We 155 
showed here that encapsulation of FliC into pectin beads for oral administration significantly 156 
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protected hamsters against C. difficile lethal challenge (Fig. 4). Indeed, at day 17 after challenge, 157 
50% of hamsters survived in the group orally vaccinated with FliC-loaded beads, whereas no survival 158 
was observed after oral vaccination with free FliC (p-value=0.041). Only 17% of hamsters (n=1) 159 
survived in the unloaded bead group. The same percentage of surviving animals was observed for the 160 
intra-rectally vaccinated group. After immunization by intra-peritoneal route, 33% of hamsters 161 
survived. Interestingly, analysis of C. difficile fecal shedding showed that, whereas all 30 animals 162 
were infected by C. difficile two days post-challenge, all surviving animals in the different groups 163 
were no more colonized at the end of the assay at 17 days post challenge. These results showed that 164 
oral vaccination with FliC-loaded pectin beads led to the best protection against C. difficile virulence 165 
in the hamster model. 166 
3.3 Antibody response induced after vaccination  167 
To correlate the observed protection with the systemic immune response induced by vaccination, we 168 
evaluated the anti-FliC response in sera. We observed an increased level of FliC-specific IgG 169 
antibodies in sera after intra-peritoneal immunizations of hamsters. In contrast, in the other groups, 170 
no significant increase of anti-FliC-specific serum IgG level was observed (Fig. 5). 171 
4 Discussion 172 
As C. difficile is a non-invasive enteropathogen, the induction of a mucosal immune response close 173 
to the site of infection appears to be a relevant choice for inducing protection. Vaccine development 174 
against non-invasive gastrointestinal infections such as enterotoxigenic Vibrio cholerae or 175 
Escherichia coli showed that the protection is conferred mainly by specific secretory IgA (sIgA) and 176 
by the induction of a memory immune response [19]. A mucosal vaccine strategy, which aims to 177 
prevent alteration of the intestinal epithelium by targeting the early stages of the C. difficile infectious 178 
process, could benefit from further attention.  179 
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Furthermore, one of the vaccine strategies against C. difficile is to target surface proteins involved in 180 
intestinal colonization. The flagellin FliC appears a promising vaccine candidate, since Ghose et al. 181 
reported that intra-peritoneal immunization with FliC and alum led to 43 to 64% of protection in a 182 
hamster model and 40 to 100% protection in a mouse model in a dose-dependent manner [12]. In our 183 
assay, intra-peritoneal immunization of hamsters with FliC led to 33% of survival against C. difficile. 184 
Compared to Ghose et al results [12], this difference of protection is probably due to the adjuvant 185 
used for immunization. Indeed, as already demonstrated, C. difficile flagellin FliC has adjuvant 186 
properties, avoiding alum use as adjuvant [12, 17]. Consequently in our study, immunizations were 187 
performed without additional adjuvant. In addition, C. difficile strain used for challenge was not the 188 
same, with probably a difference of virulence between the VPI 10463 strain used here and the 189 
630∆erm strain used in Ghose et al study, as described elsewhere [20]. Of note here, we 190 
demonstrated that the high immunogenicity of FliC enables to induce a strong systemic IgG antibody 191 
response after intra-peritoneal immunization without supplementary adjuvant.  192 
Interestingly, here we obtained a better protection with an oral vaccine consisting of FliC 193 
encapsulated into pectin beads to target colonic release than after intra-peritoneal immunization with 194 
purified FliC alone. We showed that this strategy can significantly protect 50% of hamsters from 195 
CDI (3 out of 6). However, these results should be confirmed in a larger study. This significant 196 
but partial protection confirms the multifactorial aspect of colonization, suggesting that a 197 
combination of several proteins will be necessary to trigger an efficient immune response 198 
against C. difficile colonization factors, and consequently to prevent the colonization process. In 199 
addition, according to animal variability to C. difficile infection, especially regarding immune 200 
response and microbiota, a combined vaccine could be necessary. 201 
Ghose et al. demonstrated that the protection induced by FliC immunization by intra-peritoneal route 202 
was anti-FliC IgG-mediated. In our study, the immune response induced after oral immunization with 203 
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FliC-loaded pectin beads is able to partially protect animal from death. However, no specific IgG 204 
antibody response was detected in sera. This was previously observed in another assay of oral 205 
vaccination of hamsters with the Cwp84 protease encapsulated in pectin beads. Although vaccinated 206 
hamsters were partially protected (40%) against CDI, they did not develop a systemic anti-Cwp84-207 
IgG antibody response [8]. This suggests that after vaccination by mucosal route, beside a systemic 208 
immune response, a local immune response with sIgA production could be the key factor of 209 
protection. It has been previously shown in a mouse model that parenteral immunization with 210 
flagellin can activate mucosal dendritic cells and induce an isotype switch to IgA [18]. Unfortunately 211 
secondary antibodies are not commercially available to detect specific IgA in hamsters.  212 
Here, we used the hamster model of CDI, which is highly sensitive to this infection and reflects more 213 
severe infection in human than mild infection. Our results indicate that in this model, protection 214 
could probably be related to neutralizing sIgA but other factors may play an important role in the 215 
host immune response against CDI. In particular, our immunization strategy might have generated a 216 
wider cell-based immunity that could have induced partial protection. Regarding Streptococcus 217 
pneumoniae, it has been demonstrated that multiple immune cell types are required for the induction 218 
of a protective immunity in a murine model which lacks mature B cells and fails to produce antibody 219 
[21]. Further studies are needed to specify the immune effectors induced by immunization. 220 
In this study, the least protection of hamsters observed by intra-rectal administration of FliC 221 
compared to the oral administration of FliC-loaded beads and the absence of protection for the free 222 
FliC orally treated group, is presumably due to the degradation of the free antigen by gut enzymes 223 
before it reaches the colon. This further confirms the importance of the administration route and the 224 
use of pectin beads as a delivery system for FliC.  225 
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To conclude, we showed that oral vaccination with C. difficile FliC-loaded pectin beads is partially 226 
protective against a virulent strain of C. difficile in a hamster model. In order to assess in further 227 
depth the mechanisms of protection, further studies in mouse model could inform on the 228 
protection against C. difficile colonization and a better understanding of the immune response 229 
elicited with this vaccine. This study confirms the importance of the adequacy between the 230 
administration route, the delivery system and the vaccine candidate in the design of a mucosal 231 
protective immunization strategy targeting C. difficile. 232 
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Figures 241 
242 
Figure 1. Vaccination protocol.  243 
Animals received a total of 300 µg of FliC in three administrations of 100 µg of FliC on days 0, 15 244 
and 30. Before challenge, hamsters received clindamycin and gentamicin to disrupt the intestinal 245 
microbiota. Then, hamsters were orally challenged by 7,5x10
4
 spores of C. difficile strain VPI 10463. 246 
Two days after challenge CDI was checked by detection of C. difficile in the feces. Blood samples 247 
were withdrawn before the first immunization and 15 days after the last immunization to evaluate the 248 
antibody response in sera. 249 
 250 
 251 
 252 
Figure 2. Dried pectin beads (scale bar represents 1 cm).  253 
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 254 
Figure 3. In vitro FliC release from pectin beads in Simulated Intestinal Medium (SIM) for 5h and 255 
Simulated Colonic Medium (SCM) for other 5h (n=2). 256 
 257 
Figure 4. Kaplan-Meier survival estimates after immunizations. One group was immunized with 258 
FliC-loaded beads given orally (FliC-loaded beads), one group orally received unloaded pectin beads 259 
(Unloaded beads) and three other groups were immunized with recombinant free FliC by oral (FliC 260 
oral), intra-rectal (FliC intra-rectal) or intra-peritoneal route (FliC intra-peritoneal). After challenge 261 
with spores of C. difficile VPI 10463 strain, animals were monitored for 17 days. * p-value < 0.05 262 
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 263 
Figure 5. Detection of specific IgG in animal sera by ELISA. Mean of anti-FliC-specific IgG in 264 
serum of immunized hamsters (diluted 1:500) before (D0) and after vaccination (D45). Sera of 265 
hamsters were analysed by ELISA. *: statistically significant difference p-value < 0.05 (Mann-266 
Withney U-test). 267 
 268 
 269 
 270 
 271 
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